TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03515148

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy and eccentric exercise
Description: 12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion. Previously subjects should cold their leg in ice water during sexteen minutes at a temperature of 8ºC (+/-2ºC)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vibration and eccentric exercise
Description: 12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion.During the exercise subjects will be subjected to vibration. Vibrations parameters: Frequency: 35Hz, Amplitude: 4 milimeters, Force: 3,9G
Study: NCT02822794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Capsules administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, \> 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Capsules administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, \> 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
Study: NCT00537524

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 Influenza Vaccine
Description: Two 0.5mL injections of H5N1 influenza vaccine containing 7.5μg of H5N1 antigen (A/Vietnam/1194/2004), administered 3 weeks apart, and one 0.5mL injection of H5N1 vaccine 12 months after the second dose, IM into the deltoid muscle (preferably of the non-dominant arm) or anterolateral thigh (depending on the muscle mass).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H5N1 Influenza Vaccine
Description: Two 0.25mL or 0.5mL injections of H5N1 influenza vaccine, administered 3 weeks apart, IM into the deltoid muscle (preferably of the non-dominant arm) or anterolateral thigh (depending on the muscle mass).
Study: NCT04590391

Intervention type: DEVICE
Group type: OTHER
Intervention: Visual and Auditory Breathing-swallowing Coordinated Training device
Description: This device has a structure in which a band wrapped around the chest detects the respiratory phase from changes in the lung volume, and the connected device lights a signal and sounds a sound.
Study: NCT04010110

Intervention type: DIAGNOSTIC_TEST
Intervention: visual field testing (10-2), spectral domain ocular coherence tomography and Fundus auto-fluorescence
Description: The diagnosis of toxic retinopathy was based on the positivity of at least two objective tests to confirm the subjective findings. The presence or absence of toxicity was recorded.
Study: NCT00637169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Titration of oxygen therapy
Description: Supplemental oxygen to maintain functional arterial oxygen saturations in one of two saturation target ranges.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Titration of oxygen therapy
Description: Supplemental oxygen to maintain functional arterial oxygen saturations in one of two saturation target ranges.
Study: NCT03624361

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glaucoma device implantation in a stand-alone procedure
Description: MINIject implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive Glaucoma surgical intervention.~The intervention is to be performed as stand-alone surgery.
Study: NCT01459796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilonacept
Description: Rilonacept 160 mg loading dose followed by Rilonacept 80 mg/2 mL injections qw for 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo loading dose followed by placebo injections (2 mL) qw for 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Allopurinol 50 or 100 mg, orally daily for 52 weeks as background treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Allopurinol 50 or 100 mg, orally daily for 52 weeks as background treatment.
Study: NCT03036514

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sublingual sufentanil tablet system
Description: Usage of a new patient-controlled SSTS in the postoperative phase after laminectomy or spinal fusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient-controlled intravenous analgesia
Description: Usage of classically used patient-controlled intravenous mophine-based postoperative analgesia after laminectomy or spinal fusion.
Study: NCT01813604

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Group A: Trivalent Oral Polio Vaccine
Description: Group A will receive 3 doses of trivalent oral polio vaccine (tOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Group B: Bivalent Oral Polio Vaccine
Description: Group B will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Group C: Inactivated Polio Vaccine
Description: Group C will receive 2 doses of inactivated polio vaccine (IPV) at 6 and 14 weeks of age. IPV will be administered intramuscularly using standard needle and syringe. A challenge dose of tOPV will be administered at 18 weeks of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Group D: fractional IPV (f-IPV)
Description: Group D will receive 2 doses of fractional inactivated polio vaccine (f-IPV) at 6 and 14 weeks of age. f-IPV (one-fifth dose of IPV) will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Arm E: f-IPV and bOPV
Description: Group E will receive 2 doses of f-IPV at 6 and 14 weeks of age with bOPV at 10 weeks of age. f-IPV will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
Study: NCT06391996

Intervention type: DRUG
Intervention: After exclusion of relevant contraindications, participants received subcutaneous ustekinumab/secukinumab therapy.
Description: During the treatment period, participants received either ustekinumab at weeks 0, 4, 16, and every 12 weeks thereafter until week 48, or secukinumab at weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter until week 48. The dose of ustekinumab/secukinumab was referenced to the dose used for moderate to severe plaque psoriasis. The single dose of ustekinumab was 45 mg for adult subjects weighing ≤ 100 kg, and 90 mg for subjects weighing \> 100 kg. The ustekinumab dosage for pediatric participants was 0.75 mg/kg for participants weighing \< 60 kg; 45 mg for pediatric participants weighing 60 kg to 100 kg; and 90 mg for pediatric participants weighing \> 100 kg. The secukinumab dosage was 300mg for adult humans. Pediatric participants received a dose based on their weight category ( \<50 kg, ≥50 kg): participants weighing \< 50 kg received 75 mg, those weighing ≥ 50 kg received 150 mg.

Intervention type: DRUG
Intervention: After exclusion of relevant contraindications, participants received subcutaneous ustekinumab/secukinumab therapy.
Description: During the treatment period, participants received either ustekinumab at weeks 0, 4, 16, and every 12 weeks thereafter until week 48, or secukinumab at weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter until week 48. The dose of ustekinumab/secukinumab was referenced to the dose used for moderate to severe plaque psoriasis. The single dose of ustekinumab was 45 mg for adult subjects weighing ≤ 100 kg, and 90 mg for subjects weighing \> 100 kg. The ustekinumab dosage for pediatric participants was 0.75 mg/kg for participants weighing \< 60 kg; 45 mg for pediatric participants weighing 60 kg to 100 kg; and 90 mg for pediatric participants weighing \> 100 kg. The secukinumab dosage was 300mg for adult humans. Pediatric participants received a dose based on their weight category ( \<50 kg, ≥50 kg): participants weighing \< 50 kg received 75 mg, those weighing ≥ 50 kg received 150 mg.
Study: NCT01268683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide for Injection
Description: Administered as specified in the treatment arm.
Study: NCT03401762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MCI
Description: EMG-controlled game

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MCI
Description: EMG-controlled game

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MCI
Description: EMG-controlled game

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MCI
Description: EMG-controlled game

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham MCI
Description: Sham control game
Study: NCT00491790

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Montelukast 4 mg rapid dissolving granules in sterile water given orally once
Study: NCT03401762

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham MCI
Description: Sham control game
Study: NCT02943980

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CMAC Videolaryngoscope
Description: In a randomised order we evaluate the quality of the IONM after securing the airway with the CMAC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh Laryngoscope
Description: In a randomised order we evaluate the quality of the IONM after securing the airway with the conventional Macintosh Laryngoscope
Study: NCT02426424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Watchpat
Description: WatchPAT ™ is an FDA-approved portable diagnostic device that uses the most innovative technology to ensure the accurate screening, detection, and the follow-up treatment of sleep apnea.
Study: NCT00991887

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy (XRT)
Description: The dose will be 700 gray (derived unit of ionizing radiation dose in the International System of Units) in a single fraction, using AP-PA fields calculated to midplane. No Less than 6 MV energy photons will be used, and no bolus is placed on the skin. The field covers the entire joint, the antecubital fossa and the olecranon process. A strip of skin at the antecubital area is generally shielded, but is not an absolute requirement for this study.
Study: NCT03000010

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Incisional Wound Vac

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Bandage
Study: NCT00491790

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sterile water
Description: Sterile water
Study: NCT03565406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mocetinostat Induction Phase + Ipilimumab + Nivolumab
Description: Treatment Cycle 1: Mocetinostat at a dose of 90 mg PO TIW; ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg during the 12-week induction period. The induction phase will last for 2 treatment cycles.~Treatment Cycle 2: Mocetinostat at a dose of 70 mg PO TIW ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg during the 12-week induction period. The induction phase will last for 2 treatment cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab
Description: De-escalation Phase 1: Mocetinostat will be administered 50 mg PO TIW during each 84-day treatment cycle. Ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg~De-escalation Maintenance Phase 2: Mocetinostat will be administered 40 mg PO TIW during each 84-day treatment cycle. Ipilimumab will be administered IV at a dose of 0.3 mg/kg and nivolumab will be administered IV at a dose of 1 mg/kg during period
Study: NCT03282084

Intervention type: DIAGNOSTIC_TEST
Intervention: EGD with biopsy
Description: Stop PPI and schedule for EGD with biopsy and Wireless pH capsule testing for 7-10 days later. Consider gastric emptying scan or high resolution esophageal manometry

Intervention type: DIAGNOSTIC_TEST
Intervention: EGD and impedance-pH study on PPI
Description: Continue PPI and schedule EGD and Impedance-pH study on PPI. Consider gastric emptying scan or high resolution esophageal manometry
Study: NCT01151241

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elbow arthroscopy with infraclavicular nerve block and continuous local anesthetic infusion to day 3 post op.
Description: Patients undergoing elbow arthroscopy surgery will receive standard anesthesia/analgesia, including infraclavicular nerve block and general anesthesia for surgery followed by infraclavicular catheter infusion of local anesthetic until day 3 after surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elbow arthroscopy with infraclavicular nerve block and continuous local anesthetic infusion to day 3 post op.
Description: Patients undergoing elbow arthroscopy surgery will receive standard anesthesia/analgesia, including infraclavicular nerve block and general anesthesia for surgery followed by infraclavicular catheter infusion of local anesthetic until day 3 after surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Discharge
Description: Patients will be discharged home on the first day after surgery, with infraclavicular catheter infusion of local anesthetic in place.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Discharge
Description: Patients will remain in hospital and be discharged per current discharge criteria, once the infraclavicular catheter has been removed on day 3 post op. Typical discharge occurs on day 3 or 4 post op.
Study: NCT02170727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV/ASV/BMS-791325
Study: NCT04166305

Intervention type: GENETIC
Intervention: Genetic study for SCN1A c.3184 A/G and CCL2-2518G>A polymorphism:
Description: DNA analysis: Genomic DNA will be extracted from EDTA-anticoagulated peripheral blood (QIAamp DNA Blood mini kit,QIAGEN).~Genotyping of SCN1A c.3184 A/G(rs2298771) polymorphism

Intervention type: GENETIC
Intervention: Genetic study for SCN1A c.3184 A/G and CCL2-2518G>A polymorphism:
Description: DNA analysis: Genomic DNA will be extracted from EDTA-anticoagulated peripheral blood (QIAamp DNA Blood mini kit,QIAGEN).~Genotyping of SCN1A c.3184 A/G(rs2298771) polymorphism

Intervention type: GENETIC
Intervention: Genetic study for SCN1A c.3184 A/G and CCL2-2518G>A polymorphism:
Description: DNA analysis: Genomic DNA will be extracted from EDTA-anticoagulated peripheral blood (QIAamp DNA Blood mini kit,QIAGEN).~Genotyping of SCN1A c.3184 A/G(rs2298771) polymorphism
Study: NCT00821626

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BD Directigen EZ Flu A+B
Description: Naso-pharyngeal swab and rapid flu test

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: No rapid flu test
Study: NCT04868825

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ivory Dentin Graft
Description: Ivory Dentin Graft is a bone graft material for the repair or augmentation of bone defects in dental procedures. It consists of sterile 300 - 900 μm porous particles or granules of hydroxyapatite and collagen which retain the natural form of the source porcine dentin and protein matrix. (Packed Vial: 1.00 gr; Packed Syringe: 1.0 gr)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OsteoBiol Gen-Os
Description: Comparator control device A natural porcine origin cortico-cancellous heterologous bone mix consists of sterile 250 - 1000 μm porous particles of hydroxyapatite and collagen (Packed Vial: 1.0 gr)
Study: NCT02554682

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sexual Health
Description: Psychoeducational workbook, worksheets, tip sheets, and health coaching session about sexual health, sexually transmitted disease (STD) prevention, and safe sex practices for teenager.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Alcohol Prevention
Description: Psychoeducational workbook, worksheets, tip sheets, and health coaching session about alcohol prevention and safety, underage drinking, and drinking and driving.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Teen Driving
Description: Psychoeducational workbook, worksheets, videos, tip sheets, and health coaching session about how parents can help supervise their teens' safe driving practices and how to talk with their teen about important safety topics for teen drivers.
Study: NCT04417452

Intervention type: OTHER
Intervention: Basic data collection (online survey or written form)
Description: Basic data collection is carried out by means of a questionnaire that participants can fill in outside the study centre. It contains questions about the current life situation, sleep and activity behaviour.

Intervention type: OTHER
Intervention: Basic data collection (online survey or written form)
Description: Basic data collection is carried out by means of a questionnaire that participants can fill in outside the study centre. It contains questions about the current life situation, sleep and activity behaviour.

Intervention type: OTHER
Intervention: Physical examination
Description: The physical examination takes place at the study centre and includes the measurement of height, current weight and body fat, as well as the recording of heart and circulation parameters (e.g. blood pressure measurement or determination of vascular health by means of ultrasound). General metabolic and hormonal parameters are analysed by means of a blood sample. In addition, a sugar test for diabetes diagnosis will be carried out.

Intervention type: OTHER
Intervention: Physical examination
Description: The physical examination takes place at the study centre and includes the measurement of height, current weight and body fat, as well as the recording of heart and circulation parameters (e.g. blood pressure measurement or determination of vascular health by means of ultrasound). General metabolic and hormonal parameters are analysed by means of a blood sample. In addition, a sugar test for diabetes diagnosis will be carried out.

Intervention type: BEHAVIORAL
Intervention: Psychometric examination
Description: Psychometric examination is carried out at the study centre with the help of a RIAS (Reynolds Intellectual Assessment Scales and Screening) test.

Intervention type: BEHAVIORAL
Intervention: Psychometric examination
Description: Psychometric examination is carried out at the study centre with the help of a RIAS (Reynolds Intellectual Assessment Scales and Screening) test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Recording of the adrenergic stress reaction (saliva test)
Description: The adrenergic stress reaction is recorded by a saliva test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Recording of the adrenergic stress reaction (saliva test)
Description: The adrenergic stress reaction is recorded by a saliva test.
Study: NCT02841137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: comparison of different dosages of drug towards the active comparator
Study: NCT02426424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Watchpat
Description: WatchPAT ™ is an FDA-approved portable diagnostic device that uses the most innovative technology to ensure the accurate screening, detection, and the follow-up treatment of sleep apnea.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Continuous positive airway pressure (CPAP) is a form of positive airway pressure ventilator, which applies mild air pressure on a continuous basis to keep the airways continuously open in a patient who is able to breathe spontaneously on his or her own.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Continuous positive airway pressure (CPAP) is a form of positive airway pressure ventilator, which applies mild air pressure on a continuous basis to keep the airways continuously open in a patient who is able to breathe spontaneously on his or her own.
Study: NCT00501111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3480
Description: 3 oral doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Study: NCT00447499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatuline Autogel (lanreotide acetate)
Description: Injections

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home administration
Description: Questionnaire
Study: NCT04260100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Care Self-Management Mobile Health Application
Description: In day 1, the participant will receive a Foot Care Kit consist of a mirror, a tube of lotion, a small towel, and a nail clipper. The participant will enrol in 3-hour workshop for general management of diabetes mellitus, diabetic foot care and dietary management. The participant will be invited to install Diabetes Care Self-Management Mobile Health Application. The mobile application is meant for sources of referral for diabetic foot care and dietary care, and for record purpose (diary) of any foot care activities carried out that participant needs to enter in the application during his/her home. The participant will be trained for the use of Diabetes Care Mobile Health Application. In addition, the participant will be invited to join a WhatsApp group for the medium of communication. The program will be lasting for 5 weeks.
Study: NCT03980171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: A flat dose of 1000mg IV will be given every cycle during induction. a cycle is 28 days.During maintenance 1000mg IV will be given every second cycle for upto 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: During dose escalation, the doses for venetoclax can be 400mg daily days 1-10, 800mg daily days 1-10, 400mg daily continuous or 800mg daily continuous. 6 cycles of treatment will be given during induction. Once the recommended phase 2 dose (RP2D) is established that dose will be used in dose expansion. A further 6 cycles of venetoclax will be given during maintenance if required based on response at the end of induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: During dose escalation, the doses of lenalidomide can be 15mg for days 1-21 or 20mg for days 1-21. 6 cycles of treatment will be given during induction. During maintenance the dose of lenalidomide will be 10mg continuous for a further 6 cycles if required based on response at the end of induction.